ECSP045373A - Sales de tolterodina - Google Patents

Sales de tolterodina

Info

Publication number
ECSP045373A
ECSP045373A EC2004005373A ECSP045373A ECSP045373A EC SP045373 A ECSP045373 A EC SP045373A EC 2004005373 A EC2004005373 A EC 2004005373A EC SP045373 A ECSP045373 A EC SP045373A EC SP045373 A ECSP045373 A EC SP045373A
Authority
EC
Ecuador
Prior art keywords
compounds
carbon atoms
acid
relates
tolterodine
Prior art date
Application number
EC2004005373A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045373A publication Critical patent/ECSP045373A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a nuevos compuestos farmacéuticamente activos, a composiciones farmacéuticas que contienen los mismos, a los compuestos para uso como medicamentos y al uso de los compuestos para la producción de medicamentos específicos. La presente invención también se refiere a un procedimiento de tratamiento que incluye la administración de los compuestos. De forma especifica, los compuestos son sales farmacéuticamente aceptables de tolterodina o hidroxitolterodina, en las que la sal es de un ácido seleccionado del grupo constituido por ácidos mono y dicarboxílicos alifáticos que comprenden de 7 a 24 átomos de carbono, ácidos alcanodisulfónicos que comprenden de 2 a 4 átomos de carbono, derivados de ácido naftoico que comprenden de 11 a 27 átomos de carbono, ácido maleico y ácido fumárico.
EC2004005373A 2002-04-23 2004-10-21 Sales de tolterodina ECSP045373A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/127,875 US7005449B2 (en) 2002-04-23 2002-04-23 Tolterodine salts

Publications (1)

Publication Number Publication Date
ECSP045373A true ECSP045373A (es) 2004-11-26

Family

ID=29215346

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005373A ECSP045373A (es) 2002-04-23 2004-10-21 Sales de tolterodina

Country Status (25)

Country Link
US (1) US7005449B2 (es)
EP (1) EP1496882B1 (es)
JP (1) JP2005535578A (es)
KR (1) KR20040104585A (es)
CN (1) CN1646110A (es)
AP (1) AP2004003160A0 (es)
AT (1) ATE334665T1 (es)
AU (1) AU2003237724A1 (es)
BR (1) BR0309439A (es)
CA (1) CA2483092A1 (es)
DE (1) DE60307258T2 (es)
EA (1) EA200401108A1 (es)
EC (1) ECSP045373A (es)
ES (1) ES2266828T3 (es)
HR (1) HRP20040990A2 (es)
IL (1) IL164109A0 (es)
IS (1) IS7462A (es)
MA (1) MA27197A1 (es)
MX (1) MXPA04010472A (es)
NO (1) NO20044449L (es)
OA (1) OA12810A (es)
PL (1) PL371743A1 (es)
TN (1) TNSN04212A1 (es)
TW (1) TW200306802A (es)
WO (1) WO2003090734A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496806A1 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Oral liquid tolterodine composition
AU2003304037A1 (en) * 2003-04-08 2004-11-01 Hetero Drugs Limited Novel polymorphs of tolterodine tartrate
BRPI0409492A (pt) * 2003-04-18 2006-05-02 Pharmacia & Up John Company Ll terapias de combinação
WO2005061432A1 (en) * 2003-12-24 2005-07-07 Cipla Limited Tolterodine, compositions and uses thereof, and preparation of the same
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
ITMI20060110A1 (it) * 2006-01-24 2007-07-25 Dipharma Spa Procedimento per la purificazione di tolterodina
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
ITMI20082055A1 (it) * 2008-11-19 2009-02-18 Dipharma Francis Srl Procedimento per la preparazione di (r)-tolterodina base libera
ES2533956T3 (es) * 2009-05-11 2015-04-16 Ratiopharm Gmbh Desfesoterodina en forma de una sal de ácido tartárico
IT1396373B1 (it) * 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
IT1403094B1 (it) 2010-12-09 2013-10-04 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina o un suo sale
GB201402556D0 (en) * 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
EP3826684A4 (en) 2018-07-26 2022-04-06 Sumitomo Dainippon Pharma Oncology, Inc. METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE THEREOF
CN111925294A (zh) * 2020-07-06 2020-11-13 济南大学 一种托特罗定帕莫酸盐及其制备方法
CN111728957B (zh) * 2020-07-06 2022-04-19 济南大学 一种托特罗定长效缓释微球及其制备方法
CN115814090B (zh) * 2022-11-22 2024-05-24 广州医科大学附属第一医院 烟草引发炎症的药物靶点

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
KR20000057548A (ko) * 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
PE20020547A1 (es) 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma

Also Published As

Publication number Publication date
BR0309439A (pt) 2005-02-15
ATE334665T1 (de) 2006-08-15
MA27197A1 (fr) 2005-01-03
DE60307258D1 (de) 2006-09-14
DE60307258T2 (de) 2007-10-25
OA12810A (en) 2006-07-11
EP1496882A1 (en) 2005-01-19
ES2266828T3 (es) 2007-03-01
PL371743A1 (en) 2005-06-27
AU2003237724A1 (en) 2003-11-10
NO20044449L (no) 2004-10-26
CN1646110A (zh) 2005-07-27
EA200401108A1 (ru) 2005-06-30
IL164109A0 (en) 2005-12-18
JP2005535578A (ja) 2005-11-24
AP2004003160A0 (en) 2004-12-31
TW200306802A (en) 2003-12-01
HRP20040990A2 (en) 2004-12-31
MXPA04010472A (es) 2005-07-14
US7005449B2 (en) 2006-02-28
IS7462A (is) 2004-09-20
EP1496882B1 (en) 2006-08-02
US20030199582A1 (en) 2003-10-23
CA2483092A1 (en) 2003-11-06
WO2003090734A1 (en) 2003-11-06
KR20040104585A (ko) 2004-12-10
TNSN04212A1 (fr) 2007-03-12

Similar Documents

Publication Publication Date Title
ECSP045373A (es) Sales de tolterodina
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AR009052A1 (es) Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas
AR033678A1 (es) Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
AR033346A1 (es) Acido aminoalcano carboxilicos, un procedimiento para su preparacion, intermediarios, y el uso de los mismos para la manufactura de un medicamento
BR0009042A (pt) Composto, uso do mesmo, processo para prepararum composto, composição farmacêutica, e, métodospara tratar uma doença em um animal em que aatividade de cisteìna protease contribui para apatologia e/ou sintomatologia da doença, e paratratar uma doença em um animal em que a atividadede catepsina s contribui para a patologia e/ousintomatologia da doença
ECSP088404A (es) Nuevos derivados de imidazo[4,5-b]piridina como inhibidores de la glucógeno sintasa quinasa 3, para uso en el tratamiento de demencia y trastornos neurodegenerativos
BR0014178A (pt) Derivados de ácido dicarboxìlico com propriedades farmacêuticas
BR0212346A (pt) Composto ou um sal farmaceuticamente aceitável, solvato, solvato deste sal ou uma pró-droga do mesmo, processo para a preparação do mesmo, uso deste, método para produzir um efeito inibidor de ibat em um animal de sangue quente, como um humano, em necessidade deste tratamento, e, composição farmacêutica
AR033499A1 (es) Derivado de quinazolina, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para usar en la produccion de un efecto antiangeogenico y/o reductor de la permeabilidad vascular en un animal de sangre caliente
PA8507601A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
BRPI0507786A (pt) composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos
UY27592A1 (es) Nuevo uso
BRPI0413393A (pt) fexofenadina, composição farmaceuticamente aceitável, método de tratamento antihistamìnico, composição, processo para preparar fexofenadina e uso de fexofenadina
UY27039A1 (es) Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producción
AR018139A1 (es) Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.
CO2022001853A2 (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
AR029373A1 (es) Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas
JP2018515614A5 (es)
UY27593A1 (es) Nuevos compuestos
CL2022001792A1 (es) Soluciones orales que comprenden sales de lisdexanfetamina
ES2147629T3 (es) Guanidinas de acido alquenilcarboxilico sustituidas con un grupo fluorofenilo como inhibidores del intercambio de na+/nh+, su procedimiento de preparacion y su uso como medicamento o agente diagnostico asi como el medicamento que las contiene.
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
SE9904507D0 (sv) New compounds